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ubiquitous in A. baumannii [3,5,7,8]. While the
insertion of ISAba1upstreamof blaOXA-51-like genes
has been associated with resistance to carbapen-
ems, not all isolates contain such an insertion [2].
OXA-51 and OXA-69 have been shown to hydro-
lyse carbapenems poorly [5,7], and it would be of
interest to determine whether the sequence diver-
sity of this group is a result of selection for greater
activity against the carbapenems.
NUCLEOTIDE SEQUENCE
ACCESSION NUMBERS
The novel sequences reported in this study
are deposited in the GenBank nucleotide
database under accession numbers EU019534
(OXA-79), EU019535 (OXA-80), EU019536 (OXA-
82), EF581285 (OXA-104), EF650032 (OXA-106),
EF650033 (OXA-107), EF650034 (OXA-108),
EF650035 (OXA-109), EF650036 (OXA-110),
EF650037 (OXA-111) and EF650038 (OXA-112).
ACKNOWLEDGEMENTS
This work was funded by the UK Medical
Research Council (grant no. RA0119). The authors
would like to thank N. Woodford, F. Tenover,
Z. Gu¨lay, P. Higgins and participants in the EU
ARPAC project for kindly providing isolates.
B. A. Evans1, S. Brown1, A. Hamouda1, J. Findlay1,
K. J. Towner2 and S. G. B. Amyes1*
1Centre for Infectious Diseases,
The University of Edinburgh,
Edinburgh,
2Department of Clinical Microbiology,
Queen’s Medical Centre, Nottingham, UK
*E-mail: s.g.b.amyes@ed.ac.uk
REFERENCES
1. Turton JF, Woodford N, Glover J, Yarde S, Kaufmann ME,
Pitt TL. Identiﬁcation of Acinetobacter baumannii by detection
of the blaoxa-51-like carbapenemase gene intrinsic to this
species. J Clin Microbiol 2006; 44: 2974–2976.
2. Turton JF, Ward ME, Woodford N et al. The role of ISAba1
in expression of OXA carbapenemase genes in Acinetobacter
baumannii. FEMS Microbiol Lett 2006; 258: 72–77.
3. Brown S, Amyes SGB. The sequences of seven class D beta-
lactamases isolated from carbapenem-resistant Acinetobacter
baumannii from four continents. Clin Microbiol Infect 2005;
11: 326–329.
4. Tsakris A, Ikonomidis A, Spanakis N, Pournaras S,
Bethimouti K. Identiﬁcation of a novel blaOXA-51 variant,
blaOXA-92, from a clinical isolate of Acinetobacter baumannii.
Clin Microbiol Infect 2007; 13: 348–349.
5. Heritier C, Poirel L, Fournier PE, Claverie JM, Raoult D,
Nordmann P. Characterization of the naturally occurring
oxacillinase of Acinetobacter baumannii. Antimicrob Agents
Chemother 2005; 49: 4174–4179.
6. Heritier C, Poirel L, Nordmann P. Cephalosporinase over-
expression resulting from insertion of ISAba1 in Acineto-
bacter baumannii. Clin Microbiol Infect 2006; 12: 123–130.
7. Brown S, Young HK, Amyes SGB. Characterisation of OXA-
51, a novel class D carbapenemase found in genetically
unrelated clinical strains of Acinetobacter baumannii from
Argentina. Clin Microbiol Infect 2005; 11: 15–23.
8. Merkier AK, Centron D. blaOXA-51-type beta-lactamase
genes are ubiquitous and vary within a strain in Acineto-
bacter baumannii. Int J Antimicrob Agents 2006; 28: 110–113.
Mumps vaccine failure or vaccination
scheme failure?
10.1111/j.1469-0691.2007.01811.x
We read with interest the study by Atrasheuskaya
et al. [1] concerning vaccine failure in cases of
mumps during 2002–2004 in Novosibirsk, Russia.
According to Atrasheuskaya et al. [1], the ques-
tion of whether these cases were caused by an
absence of sufﬁcient titres of antibody in response
to vaccination, or were caused by the absence of
neutralising antibody speciﬁc for the causative
mumps virus strain, cannot be answered conclu-
sively. On the basis of lessons learnt from a
descriptive epidemiological investigation of a
mumps outbreak in 214 young adults in Austria
during 2006, we hypothesise that susceptibility to
mumps infection is less likely to result from a
vaccine failure than from a vaccination scheme
failure, i.e., administration of only one of the two
recommended doses of vaccine.
Active immunisation with the Jeryl Lynn
strain of attenuated mumps virus vaccine has
been available in Austria since 1974, when a
bivalent mumps–measles (MM II) vaccine pro-
duced by Merck Sharp & Dohme was introduced
as part of the national childhood immunisation
programme. In 1994, the bivalent vaccine was
replaced by a trivalent mumps, measles and
rubella (MMR) vaccine produced by Pasteur
Merieux Connaught (containing the Jeryl Lynn
strain). Since 2001, the Priorix MMR vaccine
(Glaxo Smith Kline) has been in use, which
contains the RIT 4385 mumps strain derived
from the Jeryl Lynn strain. The vaccination
regimen includes two doses, with the ﬁrst dose
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given at an age of 1 year, and a second dose
given 6 weeks later. In Austria, mumps is not a
notiﬁable disease. Information on disease occur-
rence is based mainly on serological results
obtained by the national reference laboratory
for MMR. Sera from clinically suspected cases of
mumps are submitted by general practitioners
and hospitals. Between 2001 and 2005, 89 cases
of mumps were conﬁrmed serologically by the
reference laboratory in Austria (annual mean 18
cases; range 9–30 cases ⁄ year).
In May 2006, the Austrian Agency for Health
and Food Safety undertook an epidemiological
outbreak investigation after being informed of a
sudden increase in serologically conﬁrmed cases
of mumps in a southern province [2,3]. Atten-
dance at a youth festival on 16 April was the
common link among the 15 index cases, which
occurred in the ﬁrst week of May. A conﬁrmed
case was deﬁned as a patient: (i) with unilateral or
bilateral tender, self-limited swelling of the paro-
tid or other salivary gland, lasting ‡2 days, with
no other apparent cause, or with meningitis or
orchitis; (ii) with a clinical onset at least 14 days
(average shortest incubation period) after 16
April; and (iii) with serological conﬁrmation of
mumps infection according to ELISA-based detec-
tion of mumps-speciﬁc IgM or detection of ele-
vated mumps-speciﬁc IgG, or with virus isolated
from a throat swab. A probable case was deﬁned
as a patient: (i) with unilateral or bilateral tender,
self-limited swelling of the parotid or other
salivary gland lasting ‡2 days, with no other
apparent cause, or with meningitis or orchitis;
(ii) with a clinical onset at least 14 days (average
shortest incubation period) after 16 April 16; and
(iii) with an epidemiological link (conﬁrmed
personal contact) to a laboratory-conﬁrmed case.
In total, 143 conﬁrmed and 71 probable cases
fulﬁlled the outbreak case deﬁnition. MMR
vaccine was offered free of charge by local
health authorities. Approximately 2000 indivi-
duals were vaccinated between the end of May
and the end of July. By the fourth week of
August, the number of cases had returned to the
normal endemic level. Five of nine provinces
were affected. The female:male ratio was 1:1.74,
and the median age was 24 years (range
21–28 years). Forty-eight (22.4%) patients were
admitted to hospital, with a median length of
stay of 5 days (range 4–8.5 days). Thirty-six
(16.8%) patients developed complications;
of these, 23 patients developed orchitis,
eight developed meningitis, and seven devel-
oped pancreatitis.
Information concerning vaccination status was
available for 169 of the 214 outbreak cases.
Eighteen (10.7%) patients had been completely
vaccinated, i.e., had received two vaccine doses.
Sixty-eight (40.2%) had received only one
dose, despite the ofﬁcial two-dose vaccination
regimen. The remaining 83 (49.1%) were unvac-
cinated. Vaccine failure was the cause of suscep-
tibility to mumps infection in 18 (20.9%) of 86
vaccinated outbreak cases. In 68 (79.1%) of the
86 vaccinated outbreak cases, susceptibility to
infection could be explained by vaccination
regimen failure, i.e., administration of only one
dose of vaccine. Thus, in the case of mumps,
public health authorities should focus on ade-
quate vaccination coverage and adherence to the
recommended two-dose MMR vaccination
scheme.
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